CD8A and neoplasm: However, both quantitative and qualitative differences in the CD8 T cell response generated by different viral vectors can be found using homologous prime-boost regimens: homologous immunization with SFV provided higher tumor protection than homologous immunization with recombinant adenovirus [32].